The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | NIFTY: liposomal irinotecan in combination with 5FU and leucovorin in patients with mBTC
Changhoon Yoo, MD, PhD, University of Ulsan College of Medicine, Seoul, South Korea, discusses the findings of the NIFTY trial (NCT03524508), a multicenter comparative randomized Phase IIb study evaluating liposomal irinotecan in combination with fluorouracil (5FU) and leucovorin in patients with metastatic biliary tract cancer who have progressed from gemcitabine plus cisplatin. Patients enrolled in the experimental arm demonstrated significantly improved progression-free survival and overall survival compared to those who received fluorouracil and leucovorin. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
